Premium
Human Monocyte‐Mediated Cytotoxicity Against Herpes Simplex Virus‐Infected Cells: Activation of Cytotoxic Monocytes by Free and Liposome‐Encapsulated Lymphokines
Author(s) -
Koff Wayne C.,
Showalter Stephen D.,
Chakrabarty Mrinal K.,
Hampar Berge,
Ceccorulli Lisa M.,
Kleinerman Eugenie S.
Publication year - 1985
Publication title -
journal of leukocyte biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.819
H-Index - 191
eISSN - 1938-3673
pISSN - 0741-5400
DOI - 10.1002/jlb.37.4.461
Subject(s) - biology , monocyte , herpes simplex virus , lymphokine , cytotoxic t cell , cytotoxicity , microbiology and biotechnology , virology , virus , immunology , immune system , in vitro , biochemistry
Human peripheral blood monocytes were incubated with free or liposome‐ encapsulated human lymphokines containing macrophage‐activating factor (MAF) and tested for their effect on herpes simplex virus (HSV)‐infected target cells. Activated monocytes lysed allogeneic HSV type 2 (HSV‐2)‐infected whole human embryo cells and xenogeneic BALB/c mouse embryo cells (10E2) without any significant effect on uninfected cells, as measured by release of 51 Cr from target cells after 18 h of cocultivation. Kinetic studies revealed that lysis of virus‐infected cells occurred by 10 h following cocultivation with activated monocytes. The inability of free MAF or supernatants from MAF‐acti‐ vated monocytes to lyse HSV‐2‐infected cells suggested that direct monocyte‐ target cell contact is required for monocyte‐mediated cytotoxicity of the virus‐ infected cells. Monocytes activated with MAF suppressed the production of HSV‐2 and HSV‐1 from virus‐infected cells more than control monocytes did. In addition, monocytes treated with liposome‐encapsulated MAF selectively destroyed HSV‐2‐infected cells but left uninfected cells unharmed. The capacity of liposome‐encapsulated immunomodulators to activate human monocytes to selectively lyse HSV‐2‐infected cells has potential therapeutic benefit and should be evaluated in vivo.